ALA (α-lipoic acid) is a natural, endogenous antioxidant that acts as a PPAR-γ (peroxisome-proliferator-activated receptor-γ ) agonist to counteract oxidative stress. Thus far, the antioxidative and immunomodulatory effects of ALA on EAE (experimental autoimmune encephalomyelitis) are not well understood. In this study, we found that ALA restricts the infiltration of inflammatory cells into the CNS (central nervous system) in MOG (myelin oligodendrocyte glycoprotein)-EAE mice, thus reducing the disease severity. In addition, we revealed that ALA significantly suppresses the number and percentage of encephalitogenic Th1 and Th17 cells and increases splenic T reg -cells (regulatory T-cells). Strikingly, we further demonstrated that ALA induces endogenous PPAR-γ centrally and peripherally but has no effect on HO-1 (haem oxygenase 1). Together, these data suggest that ALA can up-regulate endogenous systemic and central PPAR-γ and enhance systemic T reg -cells to inhibit the inflammatory response and ameliorate MOG-EAE. In conclusion, our data provide the first evidence that ALA can augment the production of PPAR-γ in vivo and modulate adaptive immunity both centrally and peripherally in EAE and may reveal further antioxidative and immunomodulatory mechanisms for the application of ALA in human MS (multiple sclerosis).
INTRODUCTION
MS (multiple sclerosis) is a chronic disease of the CNS (central nervous system) that primarily affects young adults. The pathogenesis of MS is characterized by inflammation, demyelination and axonal injury [1] . EAE (experimental autoimmune encephalomyelitis) is the most widely recognized animal model of MS. Autoreactive pathogenic Th cells (e.g. Th1 and Th17 cells) have been shown to be involved in the immunopathogenesis of both MS and EAE [2] [3] [4] . Activated T-cells recruit invading macrophages, ALA (α lipoic acid) is a natural, endogenous antioxidant that is produced by both eukaryotic and prokaryotic cells and is found in foods such as broccoli, spinach and tomatoes [10] . ALA is a necessary cofactor for mitochondrial α-ketoacid dehydrogenases and thus plays an essential role in mitochondrial energy metabolism. Furthermore, ALA acts as a PPAR-γ (peroxisomeproliferator-activated receptor-γ ) agonist to enhance PPAR-γ activity and counteract oxidative stress [11] . Klotz et al. [12] demonstrated that PPAR-γ is a key negative regulator of human and mouse Th17 differentiation and selectively inhibits Th17 differentiation in a T-cell-intrinsic fashion and suppresses CNS autoimmunity. Hontecillas and Bassaganya-Riera [13] subsequently confirmed that decreased levels of PPAR-γ resulted in impaired T reg -cells (regulatory T-cells) activity, leading to a failure to suppress IFNγ (interferon γ ) production and the consequent prolongation of the inflammatory response.
However, the mechanisms of the immunomodulatory and antioxidative effects of ALA on EAE remain unclear. In the present study, we demonstrate that ALA ameliorates EAE through either the up-regulation of splenic T reg -cells and Th2 cells or the downregulation of Th1 and Th17 cells in ALA-treated MOG (myelin oligodendrocyte glycoprotein)-EAE mice in situ. Strikingly, ALA enhances the endogenous production of the nuclear receptor PPAR-γ both peripherally and centrally in EAE, which implies that PPAR-γ may play an important immunomodulatory role in ALA-mediated protection against EAE in mice.
MATERIALS AND METHODS

Mice
C57BL/6 mice (6-8 weeks old) were purchased from the National Laboratory Animal Center, Taiwan. All animal protocols were approved by the IACUC (Institutional Animal Care and Use Committee) of Taiwan.
EAE induction and treatment protocol A MOG-(35-55) peptide (M-E-V-G-W-Y-R-S-P-F-S-R-O-V-H-L-Y-R-N-G-K)
that corresponded to the sequence of the mouse MOG peptide was synthesized by QCB, a division of BioSource International, and purified to greater than 95 % purity with HPLC. Each C57BL/6 mouse was immunized on day 0 with 100 μg of MOG in 100 μl of an emulsion of CFA (complete Freund's adjuvant) and 400 μg of Mycobacterium tuberculosis H37Ra (Difco). Each mouse also received 500 ng of PTX (pertussis toxin) (List Biological Laboratories) intraperitoneally on day 0 and day 2 after immunization.
ALA in powder form was obtained from Sigma, stored at room temperature (23 • C) and dissolved in 1 M sodium hydroxide before use. This solution was titrated with 2 M HCl to pH 7.2 and an approximate salt concentration of 0.9 %. All solutions of ALA were sterile filtered. We analysed all reagents and solutions used in experiments with the LAL (Limulus amebocyte lysate) assay (HEK-Blue TM LPS Detection Kit; Invitrogen) to examine potential LPS (lipopolysaccharide) contamination, and the results were all negative (results not shown). The mice were administered ALA that was freshly diluted in sterile PBS (1 mg/100 μl per mouse per injection, equivalent to 50 mg/kg of body mass per mouse per injection) on days 6-19 post-immunization. The control mice were injected with an equal volume of PBS at the same time points.
Clinical EAE score
The clinical EAE score was assessed using the following scale: 0 = no symptoms, 0.5 = distal weak or spastic tail, 1 = completely limp tail, 1.5 = limp tail and hindlimb weakness (feet slip through cage grill), 2.0 = unilateral partial hindlimb paralysis, 2.5 = bilateral partial hindlimb paralysis, 3.0 = complete bilateral hindlimb paralysis, 3.5 = complete hindlimb and unilateral partial forelimb paralysis, 4.0 = moribund, and 5 = dead [14] .
Isolation of lymphocytes from spleens, brains and spinal cords
The mice were anaesthetized with an intramuscular injection of 100 mg of ketamine/kg of body mass (Imalgene 1000; Merial Laboratoire de Toulouse) and 20 mg of xylazine/kg of body mass (Rompum; Bayer) and were perfused transcardially through the left ventricle with 20 ml of ice-cold PBS. The spleens were harvested, placed in RPMI-1640 medium (Invitrogen Life Technologies) and minced, and the erythrocytes were depleted by treatment with Tris-buffered ammonium chloride. After centrifugation, the pellets, which represented the total splenic mononuclear cell population, were resuspended in RPMI-1640 medium. The non-adherent lymphocyte population was collected, washed and resuspended in PBS containing 1 % (v/v) FBS (fetal bovine serum) (all supplements were from Invitrogen Life Technologies).
The brains and spinal cords were dissociated by glass homogenization through a fine mesh screen using a syringe plunger and collected in 10 ml of HBSS (Hanks' balanced salt solution) containing 0.05 % collagenase D (Boehringer Mannheim Biochemicals), 0.1 μg/ml of the trypsin inhibitor N-α-TLCK (tosyllysylchloromethane) (Sigma), 10 μg/ml DNase I (Sigma) and 10 mM Hepes buffer, pH 7.4. The resulting tissue slurry was mixed at room temperature for 60 min and allowed to settle at under gravity for 30 min to remove any undigested debris. The supernatant was collected and centrifuged at 200 g for 5 min, and the pellet was resuspended in 10 ml of Ca 2 + /Mg 2 + -free HBSS per brain. Next, 5 ml of this suspension was layered carefully onto 10 ml of a modified density gradient medium (a mixture of 75 % RPMI-1640, 10 % FBS, 10 mM Hepes and 50 μg of gentamicin with 25 % Ficoll-Paque) in a 50-ml centrifuge tube. Following a 30-min centrifugation at 500 g, the overlying medium and the tissue interface were removed. The entire 10 ml of gradient medium was diluted 10-fold with HBSS and centrifuged at 300 g for 10 min [14] .
SDS/PAGE and Western blotting
Proteins were extracted from the brains and spinal cords, separated via SDS/PAGE (12 % gels) and electroblotted on to nitrocellulose membranes. The membranes were incubated for 1 h in 20 ml of blocking buffer [TBS (Tris-buffered saline) and 5% (w/v) non-fat dried skimmed milk], washed three times in TBS with 0.1 % Tween-20 and incubated overnight at 4
• C with rabbit anti-HO-1 (haem oxygenase 1) antibody (Stressgen) and anti-PPAR-γ antibody (BioVision). The membranes were washed three times and incubated for 1 h with HRP (horseradish peroxidase)-conjugated goat anti-rabbit antibody (Novus) at room temperature. Following three additional washes, the membrane-bound antibody was detected with Western Lightning Chemiluminescent Reagent Plus (PerkinElmer Life Sciences) and visualized on X-ray film. The molecular masses of HO-1, PPAR-γ and β-actin are 32, 33 and 43 kDa respectively.
Flow cytometric analysis
Prepared cells (10 6 cells in 0.1 ml of PBS) were incubated on ice and stained with the following marker-specific antibodies (0.5 μg of antibody/10 6 cells): FITC-conjugated anti-HO-1 antibody (Stressgen), FITC-conjugated anti-PPAR-γ antibody (Santa Cruz) and APC (allophycocyanin)-conjugated anti-mouse CD4 antibody (eBioscience). Either lymphocytes isolated from the CNS or erythrocyte-depleted splenocytes were stained with antimouse CD4 and stimulated with 20 ng/ml PMA plus ionomycin for 4 h, with the final 2 h in the presence of monensin [15] . Erythrocyte-depleted splenocytes were use used to perform the ex vivo study, MOG stimulation (25 μg MOG/ml overnight and last 4 h with monensin) and MOG-specific Th lineages were measured. After fixation in 4 % (v/v) formaldehyde for 20 min, the cells were stained with an FITC-conjugated mAb (monoclonal antibody) to IFNγ , an FITC-conjugated mAb to FoxP3, a PE (phycoerythrin)-conjugated mAb to IL-17 (interleukin 17), a PEconjugated mAb to IL-4, a PE-conjugated mAb to CD25 or isotype control mAbs, according to the manufacturer's instructions (BD Biosciences), in the presence of 0.5 % saponin for permeabilization (eBioscience). Flow cytometric analysis was performed with a fluorescence-activated cell sorter (FACS; FACSCalibur, Becton Dickinson), and the data were analysed with CellQuest software. The results were analysed using WinMDI software.
Antigen-specific proliferation
Splenocyte cell suspensions were isolated on day 21 from MOG-(35-55)-immunized mice that had been treated with ALA or left untreated. The pooled splenocytes from six mice from the same group were plated in triplicate in 96-well round-bottomed plates at 2×10 5 cells/well in 200 μl of complete RPMI-1640 medium supplemented with 2 mM L-glutamine, 25 mM Hepes, 100 units/ml penicillin, 100 μg/ml streptomycin, 5.5×10
− 5 M 2-mercaptoethanol and 5 % (v/v) FBS (all the supplements were from Invitrogen Life Technologies) that contained 0-10 μg/ml MOG-(35-55) (Enzo Life Sciences). On day 3, 1 Ci/well [ 3 H]-thymidine (Amersham Pharmacia Biotech) was added, cells were cultured for an additional 6 h, and harvest proliferation was assessed by [ 3 H]-thymidine incorporation detected with a TopCount scintillation counter (Packard, PerkinElmer). The supernatants were collected after a 72-h culture at 37
• C in 5 % (v/v) CO 2 , and the cytokine concentrations were determined with ELISA using antibody pairs specific for IL-4, IL-17, IFNγ and TNF-α (tumour necrosis factor α) (BD Biosciences).
Adoptive transfer
Prepared splenocytes were isolated from donor mice treated with ALA or left untreated 21 d after MOG-(35-55) immunization, and 2×10 7 cells were injected intravenously into recipients. The recipient mice were immunized with 50 μg of MOG-(35-55) peptide in CFA and administered 500 ng of PTX intraperitoneally on days 0 and 2.
Statistical analysis
Disease scores were analysed using repeated-measures AN-OVA. A significant difference in disease progression between two groups corresponds to P < 0.05 for a two-sided significance test. Where significant differences were found, the TukeyKramer multiple comparisons test was used to identify differences between individual groups. The significance of the realtime PCR results was determined using the Newman-Keuls test.
RESULTS
ALA ameliorates EAE and represses inflammatory effects in situ
Marracci et al. [16] first demonstrated that ALA suppresses EAE induced by PLP (proteolipid protein)-(139-151) in SJL mice. We found a similarly delayed onset of disease and a significantly lower clinical score in the MOG-EAE mice treated with ALA compared with the controls ( Figure 1A) . Correspondingly, histopathological analysis revealed abundant inflammatory cell infiltration in the control spinal cords but only minor inflammatory cell infiltration in the spinal cords from the ALA-treated MOG-EAE mice ( Figure 1D ). This demonstrates a protective effect of ALA in EAE both clinically and histologically and is consistent with previous reports [17] .
ALA up-regulated antioxidants in situ: PPAR-γ but not HO-1 Interestingly, the antioxidant effects of ALA in EAE has not been reported previously. Thus we directly investigated the in situ expression levels of potential antioxidant proteins, including HO-1 and PPAR-γ , in MOG-EAE mice. We observed significantly increased expression of endogenous PPAR-γ in both the brain and spinal cord of the ALA-treated MOG-EAE mice compared with the controls (Figures 1B and 1C) . However, the HO-1 expression levels were not significantly changed in the brains and were significantly decreased in the spinal cords of the ALA-treated MOG-EAE mice. This in situ augmentation of endogenous PPAR-γ in ALA-treated MOG-EAE mice, suggests an antioxidant benefit that leads to immunoprotection.
ALA counteracts encephalitogenic Th1 and Th17 subsets in situ
To investigate the effects of ALA treatment on Th lineages, we isolated mononuclear cells from the CNS of mice either treated with ALA or treated with PBS as a control on day 21 after EAE induction. There were fewer CD4 + T-cells (Th17, Th4 and Th1) in the CNS in the ALA group compared with the control group, as determined by flow cytometry. However, we found a significantly higher proportion of Th2 cells, a lower level of Th17 cells and a trend towards decreased Th1 cells in situ in the ALA-treated MOG-EAE mice compared with the controls (Figure 2 ), which suggests that ALA has the capacity to suppress Th17 and Th1 cells and to enhance Th2 cells in situ to protect mice from EAE.
ALA up-regulates HO-1 and PPAR-γ peripherally, but only PPAR-γ in situ Interestingly, we disclosed a significantly elevated expression of endogenous PPAR-γ in both the brain and the spinal cord from the ALA-treated MOG-EAE mice compared with the controls ( Figure 1C) . Upon further examination of the antioxidant potential of ALA via the peripheral expression of HO-1 and PPAR-γ , we observed marked increases in the levels of splenic HO-1 and splenic PPAR-γ in the ALA-treated mice with EAE ( Figures 3A  and 3B ). We used flow cytometry to address whether ALA affected the intensity of cellular HO-1 and PPAR-γ expression in splenocytes. We observed a significantly increased MFI (mean fluorescence intensity) for PPAR-γ and a slight trend towards an increased MFI for HO-1 using equal numbers of splenic lymphocytes from the ALA-treated MOG-EAE mice and the control mice ( Figure 3C ). Overall, we observed that ALA not only causes a central up-regulation of PPAR-γ in the CNS, but is also a potent inducer of PPAR-γ and HO-1 in the peripheral immune system, particularly in the augmentation of PPAR-γ expression.
ALA enhances splenic T reg -cells and suppresses MOG-specific Th1
Both the PPAR-γ activation caused by the administration of a PPAR-γ agonist and the up-regulation of endogenous HO-1 have been shown to enhance the expression of Th2 cytokines, such as IL-4, to ameliorate inflammation in CNS-demyelinating diseases such as MS [18, 19] . Therefore we analysed subsets of splenic Th lineages using flow cytometry on day 21 after EAE induction. RBC (red blood cell)-depleted splenocytes were stained with antimouse CD4 and stimulated with 20 ng/ml PMA plus ionomycin for 4 h, with the final 2 h in the presence of monensin. Interestingly, we observed a significantly higher proportion of splenic Th2 cells ( Figure 4A ) and a markedly increased number of splenic T reg -cells (CD25 + FoxP3 + CD4 + cells) from the ALA-treated MOG-EAE mice ( Figures 4B and 4C) . However, no significant difference in either splenic Th1 or Th17 cells was observed in this non-specific stimulation assay. In addition, we conducted further ex vivo study where we isolated RBC-depleted splenocytes from mice of EAE on day 14 for antigen specific stimulation via MOG (25 μg of MOG/ml overnight and last 4 h with monensin) to measure these MOG-specific Th lineages. We gated CD4
+ cells for analysis and revealed a significant elevated ratio of Th1 cells (IFNγ + /CD4cells) and mild elevation of Th17 (IL17 + /CD4 cells) in the control group compared with the ALA treatment group (see Supplementary Figure S1 at http://www.clinsci. org/cs/125/cs1250329add.htm). Together, the up-regulation of splenic T reg -cells and down-regulation of inflammatory response suggests a role for the anti-inflammatory potential of ALA in EAE.
Splenocytes from ALA-treated mice inhibit T-cell proliferation and ameliorate EAE severity after adoptive transfer
To investigate the suppressive potential of ALA on T-cellmediated effector functions in EAE, we further analyse the MOGspecific T-cell response and in vivo adoptive transfer examination. We isolated splenocytes from ALA-treated MOG-EAE mice and from control mice on day 14 post-EAE. The cultured splenocytes were treated with various concentrations of MOG as specific antigen. A mild suppressive effect on T-cell proliferation was observed in the ALA group compared with the control ( Figure 5A ).We also investigated further pro-and antiinflammatory cytokines in terms of the response of IL-17, IFNγ , TNF-α and IL-4 to antigen-specific stimulation in ALA-treated and control groups, respectively ( Figure 5B) . Surprisingly, we found that all the cytokines were significantly suppressed in the ALA-treated group compared with the controls. To further elucidate the in vivo immunomodulation of T-cell function by ALA, we isolated splenocytes from the ALA-treated MOG-EAE mice or the controls on day 21 after MOG-(35-55)/CFA induction and passively transferred these cells into C57BL/6 recipients. The recipients of splenocytes from the ALA-treated MOG-EAE mice had a lower clinical score and a more rapid recovery from disease than the recipients of splenocytes from the controls (Figure 5C ). This result indicates that splenocytes from ALA-treated mice preserve their immunomodulatory competency to decrease neuroinflammation in EAE, which implies that the immunomodulation of ALA may directly repress immunopathogenic T-cells in MS patients. Nevertheless, additional evidence is needed to confirm this phenomenon.
DISCUSSION
The immunopathogenesis of MS is an extremely complicated process and difficult to explore adequately through in vitro analysis. EAE has become the most popular animal model of MS for CNS inflammation and demyelination research into complex pathogenic mechanisms and for testing novel or developing therapeutic agents [20] . ALA has been shown to have a protective role against oxidative injury in various diseases, including diabetes [21, 22] , hypertension [23, 24] , ischaemia-reperfusion [25] , diabetic polyneuropathy [26] [27] [28] and AD (Alzheimer's disease) [29] . However, the treatment of MS with ALA has been considered as a complementary adjunctive therapy only [30, 31] . The protective mechanism of ALA in EAE has been partially elucidated by previous studies [16, 17, 32] , but there are limited data on the immunologic effects on EAE of the inhibition of cytokine secretion and adhesion molecule expression. In the study by Marracci et al. [16] , ALA inhibited the migration of T-cells into the CNS by acting as an MMP (matrix metalloproteinase) inhibitor in the PLP-induced EAE model. In the report by Morini et al. [17] , ALA was used to treat MOG-induced EAE through a mechanism involving the inhibition of MMP and IFNγ and IL-4 production by MOG-reactive T-cells. The MOG-specific T-cells exhibited decreased production of IFNγ and IL-4, suggesting an immunosuppressive activity of both the Th1 and Th2 cytokines. In a pilot clinical study, Yadav et al. [31] demonstrated that oral ALA may exert its immunological benefits by down-regulating adhesion molecules.
We did not test the role of adhesion molecules in the ALAtreated MOG-EAE model; however, our data showed a corresponding decrease in the infiltration of inflammatory leucocytes into the CNS and a trend towards an increased amount of Th2 cells in situ in ALA-treated MOG-EAE mice. Previously, Mestre et al. [33] demonstrated that a cannabinoid agonist interferes with the progression of a chronic model of MS by down-regulating adhesion molecules [ICAM-1 (intercellular adhesion molecule 1) and VCAM-1 (vascular cell adhesion molecule)] through the upregulation of PPAR-γ . This may imply that PPAR-γ produced by ALA has the ability to inhibit the migration of peripheral proinflammatory Th17 and Th1 cells into the CNS. In our study, Th1 and Th17 subsets in CNS were significantly suppressed (Figure 2A) . Accordingly, we hypothesize that ALA inhibits the infiltration of inflammatory cells through the decreased expression of adhesion molecules via enhancing the endogenous production of PPAR-γ . Nevertheless, further study is needed to identify the adhesion molecules associated with the PPAR-γ -mediated immunomodulation of ALA-treated MOG-EAE mice.
ALA is a PPAR-γ agonist in CV-1 monkey epithelial cells [11] . ALA can induce PPAR-γ expression and prevent a decrease in PPAR-γ protein levels in the aorta and heart in chronically glucose-treated rats, preventing an increase in systolic BP (blood pressure) and aortic superoxide production and attenuating the development of insulin resistance [23] . ALA also significantly induced PPAR-γ activation in platelets and increased intracellular amounts of PPAR-γ , thus enhancing the anti-platelet activity [34] . Several studies have reported that PPAR-γ agonists possess both anti-oxidative and anti-inflammatory properties in EAE [19, 35, 36] . PPAR-γ agonists suppressed the proinflammatory molecules produced by microglial cells and astrocytes [37] . PPAR-γ also inhibits the interaction between leucocytes and endothelial cells via the inhibition of adhesion molecule expression [38] . The increased expression of PPAR-γ and the subsequent inhibition of glial cell activation were hypothesized to have an anti-inflammatory effect in EAE [35] . Previously, an association between the PPAR-γ gene polymorphism P12A and the delayed onset of MS was reported [39] . Natarajan et al. [40] observed that PPAR-γ -deficient heterozygous mice exhibited an increased Th1 response compared with wild-type controls, implying that the induction of PPAR-γ during local inflammation may produce anti-inflammatory effects, such as changes in the local IL-4 concentration, and may down-regulate the Th1 inflammatory response, similar to our observations (Figure 2) . Even Th1 and Th17 subsets in the CNS were significantly suppressed ( Figure 2A) ; however, these phenomena are not consistent in splenic Th subsets under non-specific stimulation ( Figure 4A ). Nevertheless, we found further evidence of consistent expression of splenic Th subsets under antigen-specific stimulation and we also revealed Th1 and Th17 subsets were repressed correspondingly under MOG-(35-55) stimulation in the ALA-treated group (see Supplementary Figure S1 ). Accordingly, we hypothesize that PPAR-γ produced by ALA had the ability to inhibit the inflammation whether in the CNS or in the peripheral environment.
The antioxidant effects of ALA are mediated by the induction of HO-1 in aortic smooth muscle cells, which provides a protective effect in vascular disease [23, 41] . Our previous study demonstrated that erythropoietin induces the production of endogenous HO-1 and represses the inflammatory response in EAE [42] . Similarly, PPAR-γ agonists inhibit activated microglia via the production of HO-1 [43] . However, in the present study, ALA induced elevated HO-1 levels in EAE mice only peripherally, not centrally. One possible explanation for this finding is that ALA decreased the infiltration of inflammatory cells into the CNS via the production of PPAR-γ both centrally and peripherally, but the role of HO-1 during ALA-treated MOG-EAE was overwhelmed by the dominant effects of PPAR-γ .
Encephalitogenic Th17 cells are the essential pathogenic cells of EAE [44] . Th1 cells can facilitate the invasion of Th17 cells into the CNS during EAE [45] , and the CNS-derived Th2 cytokine IL-4 is crucial for the regulation of inflammation in EAE [46] . We explored the immunomodulatory mechanisms of this phenomenon. Our data confirmed that ALA counteracts both the Th17-and Th1-mediated inflammatory responses in situ during EAE. ALA increased IL-4 markedly in the spinal cord and decreased inflammation and the EAE clinical score, suggesting that this immunomodulation may be partly dependent on the increased level of IL-4 [47] . Ponomarev et al. [46] demonstrated that an increased expression of IL-4 in glial cells was associated with a reduced severity of EAE and that IL-4 production in the CNS is essential for controlling autoimmune inflammation by inducing an alternative regulation of microglial cells.
Kohm et al. [48] observed that T reg -cells effectively inhibit both the proliferation of MOG-specific Th1 cells and their production of cytokines and that the adoptive transfer of T regcells confers significant protection from EAE. The expansion of myelin-reactive T reg -cells can prevent disease relapse when it occurs after the onset of clinical EAE [49] . In our study, a high level of splenic T reg -cells may provide an immunosuppressive effect to protect ALA-treated MOG-EAE mice. Accordingly, the enhancement of PPAR-γ expression may contribute to the overexpression of peripheral T reg -cells and inhibit the increased inflammation in ALA-treated MOG-EAE mice, as observed in our study. Furthermore, we identified a significant suppression of MOG-specific T-cell proliferation and a lower clinical severity after the adoptive transfer of splenocytes from the ALA-treated group. However, the in vitro data on IL-4 in Figure 5 (B) showed somewhat inconsistent results with Figure 2 , but the in vivo transfer study supported decreased inflammation in the ALA treatment group. These effects may be attributed, at least in part, to the upregulation of peripheral T reg -cells and down-regulation of the Th1 lineage in the ALA-treated MOG-EAE mice.
However, some limitations of this work remain. Dunn et al. [50] first revealed that PPAR-δ limits the expansion of encephalitogenic Th cells in EAE in a murine gene knockout model. Our study did not investigate the role of PPAR-δ in an ALA-treated MOG-EAE model. Secondly, Schillace et al. [51] found that ALA can induce an increase in cAMP, a known immunosuppressant, in human T-cells and NK (natural killer) cells, which may suppress the inflammation associated with EAE or MS. We did not study the role of NK cells in this ALA-treated MOG-EAE model. Nevertheless, the results presented here advance our understanding of the anti-inflammation effect of ALA in EAE, and further studies should be conducted to address the concerns raised.
In conclusion, ALA can augment the induction of endogenous PPAR-γ centrally and peripherally, repressing Th1 and Th17 responses in situ and enhancing systemic Th2 and T reg -cell responses to ameliorate MOG-EAE severity. We also provide further evidence of the immunomodulatory and antioxidant effects of ALA via up-regulating endogenous PPAR-γ to modulate the central and peripheral immune responses to contribute to neuroprotection in EAE.
CLINICAL PERSPECTIVES
r ALA had been used as a complementary and alternative medicine treatment for MS patients, but direct evidence of its effects is lacking.
r In our MOG-EAE model, ALA up-regulated the production of endogenous PPAR-γ in vivo and modulated adaptive immunity both centrally and peripherally in EAE.
r These finding suggest that PPAR-γ may play an important immunomodulatory role in ALA-mediated protection against EAE in mice and potentially in human MS.
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